Remyelination in multiple sclerosis: Cellular mechanisms and novel therapeutic approaches
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
The myelin sheath that coats axons allows rapid propagation of electrical impulses across the nervous system. Oligodendrocytes (ODs) are myelin‐producing cells of the central nervous system (CNS) responsible for wrapping the axons of neurons. Multiple sclerosis (MS) is a demyelinating disease of the CNS identifiable by white and gray matter lesions. These lesions consist of axons that have lost their myelin through an autoimmune response to myelin and ODs. Current treatments for MS target the autoimmune aspect of the disease. However, these immunomodulators do not directly enhance the process of remyelination. The ability to remyelinate lesions can be enhanced by neural progenitor cells that can differentiate into ODs and replace lost myelin, although successful remyelination is complex and dependent on multiple factors. The restoration of lost myelin might protect the axon from degeneration and restore optimal conduction of impulses in MS patients, requiring further research on proremyelinating therapies. The combination of immunomodulators and remyelinating enhancers might be the best course of treatment for many MS patients. This Review discusses demyelination in MS, the mechanisms of remyelination, and current therapies designed to promote remyelination in MS patients. © 2014 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination
Miron, V. E., Boyd, A., Zhao, J.-W., Yuen, T. J., Ruckh, J. M., Shadrach, J. L., van Wijngaarden, P., Wagers, A. J., Williams, A., Franklin, R. J. M., et al. (2013) · Nature Neuroscience · doi:10.1038/nn.3469 · Cited by 1,777
Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)
Constantinescu, C. S., Farooqi, N., O'Brien, K., & Gran, B. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01302.x · Cited by 1,523
Premyelinating Oligodendrocytes in Chronic Lesions of Multiple Sclerosis
Chang, A., Tourtellotte, W. W., Rudick, R., & Trapp, B. D. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa010994 · Cited by 991 · cited 4×
“Several explanations for this limitation include a depletion of available OPCs resulting from extensive rounds of remyelination, axonal damage resulting in an inability to associate with myelin (Chang et al., 2002), and formation of glial scars (Fawcett and Asher, 1999) that might impede migration of OPCs to demyelina…”
BackgroundInfluentialOligodendrocyte Dynamics in the Healthy Adult CNS: Evidence for Myelin Remodeling
Young, K. M., Psachoulia, K., Tripathi, R. B., Dunn, S.-J., Cossell, L., Attwell, D., Tohyama, K., & Richardson, W. D. (2013) · Neuron · doi:10.1016/j.neuron.2013.01.006 · Cited by 919 · cited 1×
“Whether this occurrence is the result of unfavorable conditions that exist within the demyelinated lesions or a natural mechanism for late-born ODs to form shorter segments along axons remains to be ascertained (Young et al., 2013).”
BackgroundAcute axonal injury in multiple sclerosis: Correlation with demyelination and inflammation
Bitsch, A. (2000) · Brain · doi:10.1093/brain/123.6.1174 · Cited by 898 · cited 1×
“Extensive research has been conducted on axon damage with the goal of understanding the nature of the different subtypes of MS (Bitsch et al., 2000; Kornek et al., 2000).”
BackgroundHigh cholesterol level is essential for myelin membrane growth
Saher, G., Brügger, B., Lappe-Siefke, C., Möbius, W., Tozawa, R.-I., Wehr, M. C., Wieland, F., Ishibashi, S., & Nave, K.-A. (2005) · Nature Neuroscience · doi:10.1038/nn1426 · Cited by 799 · cited 1×
“Knockout mice with a mutation in the squalene synthase gene, an enzyme necessary for cholesterol synthesis, develop myelin in the CNS at a delayed rate compared with wild-type mice (Saher et al., 2005).”
BackgroundCortical lesions in multiple sclerosis
Kidd, D., Barkhof, F., McConnell, R., Algra, P. R., Allen, I. V., & Revesz, T. (1999) · Brain · doi:10.1093/brain/122.1.17 · Cited by 766 · cited 1×
“MS patients suffer from lesions in both white and gray matter of the CNS (Kidd et al., 1999; Chang et al., 2012; Damasceno et al., 2014).”
BackgroundMechanisms of axon ensheathment and myelin growth
Sherman, D. L., & Brophy, P. J. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1743 · Cited by 668
Wolswijk, G. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-02-00601.1998 · Cited by 562
Cited by
Butyrate suppresses demyelination and enhances remyelination
Chen, T., Noto, D., Hoshino, Y., Mizuno, M., & Miyake, S. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1552-y · Cited by 229
Microglial phagocytosis in aging and Alzheimer's disease
Gabandé‐Rodríguez, E., Keane, L., & Capasso, M. (2020) · Journal of Neuroscience Research · doi:10.1002/jnr.24419 · Cited by 127
Regev, K., Healy, B. C., Khalid, F., Paul, A., Chu, R., Tauhid, S., Tummala, S., Diaz-Cruz, C., Raheja, R., Mazzola, M. A., et al. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2016.5197 · Cited by 68
Glial Cells and Integrity of the Nervous System
von Bernhardi, R., Eugenín-von Bernhardi, J., Flores, B., & Eugenín León, J. (2016) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-40764-7_1 · Cited by 67
Pentón-Rol, G., Marín-Prida, J., & Falcón-Cama, V. (2018) · Behavioral Sciences · doi:10.3390/bs8010015 · Cited by 50
Metadata
- Authors
- Olsen, J. A., & Akirav, E. M.
- Venue
- Journal of Neuroscience Research
- Publisher
- Wiley
- Published
- 2014-10-07
- Volume
- 93
- Issue
- 5
- Pages
- 687-696
- ISSN
- 0360-4012 (ISSN-L)
- 1097-4547
- OpenAlex
- W2168974755
- Cited by
- 48
- References
- 22
- FWCI
- 4.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.